TuHURA Biosciences vs NextCure
HURA and NXTC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HURA and NXTC compare
TuHURA Biosciences is the larger company, worth 2.9 times as much as NextCure ($89.2M against $30.7M).
NextCure scores higher on the StockData Score (5 against 0 for TuHURA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HURA | NXTC |
|---|---|---|
| Size and price | ||
| Market cap | $89.2M | $30.7M |
| Share price | $1.40 | $6.70 |
| Change, 1 year | −31.7% | −32.2% |
| Change, 5 years | −99.9% | −90.7% |
| Beta (5Y) | 1.98 | 2.04 |
| Employees | 22 | 40 |
| StockData Score | ||
| Total score | 0 | 5 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 4.8× | 2.5× (better) |
| FCF yield | −33.5% | – |
| Profitability | ||
| Return on equity | −161% (better) | −205% |
| Return on invested capital | – | −320% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 0.18 | 3.47 (better) |
| Altman Z-score | −3.21 (better) | −32.32 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | −22.6% | – |
| Shareholder yield | −22.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 14.1% | 37.9% |
| Held by insiders | 4.9% | 22.9% |
| Insider net buying, 12 months | – | $1.7M |
| Short interest, % of float | 10.2% | 5.2% |
Go deeper
- HURA stock overview
- HURA income statement
- HURA valuation and score
- NXTC stock overview
- NXTC income statement
- NXTC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.